| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00520-017-3772-Y |
| P698 | PubMed publication ID | 28589310 |
| P50 | author | Kate Webber | Q39061491 |
| Lisa G Horvath | Q58333064 | ||
| Arun V Krishnan | Q79461131 | ||
| P2093 | author name string | David Goldstein | |
| Matthew C Kiernan | |||
| Susanna B Park | |||
| Frances Boyle | |||
| Keith Cox | |||
| Peter Grimison | |||
| J Matt McCrary | |||
| Craig R Lewis | |||
| Sally Baron-Hay | |||
| IN FOCUS Delphi working party | |||
| P2860 | cites work | Psychometric evaluation of two scales assessing functional status and peripheral neuropathy associated with chemotherapy for ovarian cancer: a gynecologic oncology group study | Q80094079 |
| The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20 | Q81776925 | ||
| Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy | Q82719969 | ||
| Development and psychometric evaluation of the chemotherapy-induced peripheral neuropathy assessment tool | Q83224751 | ||
| The validity of neuropathy and neuropathic pain measures in patients with cancer receiving taxanes and platinums | Q83487760 | ||
| Diagnosis and treatment of pain in small-fiber neuropathy | Q24601427 | ||
| Neuropathic pain phenotyping by international consensus (NeuroPPIC) for genetic studies: a NeuPSIG systematic review, Delphi survey, and expert panel recommendations | Q26782743 | ||
| Chemotherapy-induced peripheral neurotoxicity: a critical analysis | Q27010318 | ||
| European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the [...] | Q28288249 | ||
| Grading of chemotherapy-induced peripheral neuropathy | Q33977591 | ||
| Research guidelines for the Delphi survey technique. | Q34092057 | ||
| Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline | Q34415239 | ||
| Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies | Q34788181 | ||
| Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire | Q35248222 | ||
| Distal symmetric polyneuropathy: a definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation | Q36019152 | ||
| Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy | Q36394578 | ||
| The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings | Q36551631 | ||
| The total neuropathy score: a tool for measuring chemotherapy-induced peripheral neuropathy | Q37055947 | ||
| Barriers and facilitators to implementing shared decision-making in clinical practice: update of a systematic review of health professionals' perceptions | Q37254654 | ||
| Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin | Q37404101 | ||
| Aspects relevant for functioning in patients with ankylosing spondylitis according to the health professionals: a Delphi study with the ICF as reference | Q37525866 | ||
| Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools | Q37666056 | ||
| Evaluation of chemotherapy-induced peripheral neuropathy using current perception threshold and clinical evaluations | Q37672348 | ||
| Measures of chemotherapy-induced peripheral neuropathy: a systematic review of psychometric properties | Q37825579 | ||
| Content validity of symptom-based measures for diabetic, chemotherapy, and HIV peripheral neuropathy | Q38905482 | ||
| The Association of Chemotherapy-Induced Peripheral Neuropathy Symptoms and the Risk of Falling. | Q39763516 | ||
| The Delphi technique: a worthwhile research approach for nursing? | Q40634646 | ||
| Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale | Q44650556 | ||
| Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02. | Q46069967 | ||
| Gait, balance, and patient-reported outcomes during taxane-based chemotherapy in early-stage breast cancer patients. | Q47805054 | ||
| Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials | Q48051912 | ||
| Multi-center assessment of the Total Neuropathy Score for chemotherapy-induced peripheral neurotoxicity. | Q51939446 | ||
| Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. | Q53362023 | ||
| Characterization and diagnostic evaluation of chronic polyneuropathies induced by oxaliplatin and docetaxel comparing skin biopsy to quantitative sensory testing and nerve conduction studies | Q58455979 | ||
| The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale | Q58874455 | ||
| Total neuropathy score: validation and reliability study | Q73187357 | ||
| Cutaneous innervation in chronic inflammatory demyelinating polyneuropathy | Q78347033 | ||
| P433 | issue | 11 | |
| P921 | main subject | peripheral neuropathy | Q945238 |
| Chemotherapy-induced peripheral neuropathy | Q17153857 | ||
| P304 | page(s) | 3485-3493 | |
| P577 | publication date | 2017-06-07 | |
| P1433 | published in | Supportive Care in Cancer | Q15766919 |
| P1476 | title | Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey | |
| P478 | volume | 25 |
| Q90701662 | Acupuncture for Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer Survivors: A Randomized Controlled Pilot Trial |
| Q61797229 | Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy |
| Q88014319 | Associations Between Perceived Stress and Chemotherapy-Induced Peripheral Neuropathy and Otoxicity in Adult Cancer Survivors |
| Q90023453 | Characterizing patient-clinician chemotherapy-induced peripheral neuropathy assessment and management communication approaches |
| Q47564629 | Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial |
| Q57164540 | Evaluation of the effects of sensorimotor exercise on physical and psychological parameters in breast cancer patients undergoing neurotoxic chemotherapy |
| Q91638203 | Experimental Study of Shenfu Injection on the Prevention and Treatment of Paclitaxel Chemotherapy DRG Neuron Injury |
| Q47344383 | Pharmacotherapy options for managing chemotherapy-induced peripheral neurotoxicity |
| Q90577394 | Recent advances in understanding chemotherapy-induced peripheral neuropathy |
| Q64934304 | Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy. |
Search more.